Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis
NCT ID: NCT03441893
Last Updated: 2023-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
300 participants
INTERVENTIONAL
2015-01-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Parasitic Infections and Ulcerative Colitis: Combining Anti-parasitic and Immunomodulatory Treatments May Achieve Remission
NCT06583863
Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis
NCT03110198
Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis
NCT05538026
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
NCT01124149
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
NCT00408174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants Diagnosis of UC will be confirmed using standard clinical, endoscopic, radiographic, and pathological criteria according to the Montreal classification of extent and severity of ulcerative colitis (Silverberg MS et al. 2006). UC categories include proctitis, left-sided colitis, and extensive colitis or pancolitis. Activity of the disease will be measured by Mayo Clinic score that consists of 4 items: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and patient's functional assessment (D'Haens G et al. 2007). The disease duration will be measured in years from the first time of symptoms onset.
UC patients hospitalized in coloproctology department of Republic clinical hospital №1 will be examined before surgery and receiving of medications. Additional cohort groups: the 1st one will include UC patients infected with B. hominis which will be examined before and after taking nitazoxanide (monotherapy), the 2nd group will include UC patients infected with B. hominis before and after taking nitazoxanide and mesalazine (combination therapy) and 3rd one - patients with UC infected with B. hominis before and after taking mesalazine (monotherapy).
The control group will include residents of Tashkent region without any complaints from the gastrointestinal tract, who will apply to the clinic for planned medical examinations. Suggested age of the population from 17 to 90 years
Exclusion criteria Patients with diagnosis of Crohn's disease will be excluded from the analysis. Other exclusion criteria are toxic megacolon, abdominal abscess, symptomatic colonic stricture, stoma, a history of colectomy, an increased risk of infectious complications (e.g. as a result of recent pyogenic infection, enteric pathogens detected in microbiological stool analysis, active or latent tuberculosis, immunodeficiency, hepatitis B or C, or recent live vaccination), clinically meaningful laboratory abnormalities, pregnancy or lactation, unstable or uncontrolled medical disorders, an anticipated requirements for major surgery, colonic dysplasia or adenomas, and malignant neoplasms.
For additional groups except the above mentioned the followed patients will be excluded: individuals who were operated, ever used immunosuppressants or biological drugs, infected with intestinal pathologenic bacteria, including Clostridium difficile, Salmonella spp, Shigella spp, Campylobacter spp, Yersinia spp, and Mycobacteria.
Parasitological method Collection of stool samples. Three stool samples for parasitological examination will be taken from both control subjects and UC patients at 2 days interval before therapy (all participants) and in the 2nd week of monotherapy therapy with nitazoxanide, nitazoxanide in combination with mesalazine and monotherapy with mesalazine and in 6th and 12th weeks from beginning of the therapy. Stool samples (1-2g.) will be collected in individual containers, with 5 ml of Turdiev's preservative provided conservation and staining of proozoa cysts and eggs of worms for a year. The Turdiev's preservative includes: 80 ml of 0.2% aqueous solution of sodium nitrite, 10 ml of formaldehyde, 2 ml of glycerin, 8 ml of Lugol's solution, 250 ml of distilled water.
Stool samples (1-2g.) for detection of C. parvum (Cryptosporidium parvum) will be collected in individual empty containers no less 1 hour before parasitological examination.
Microscopy. Parasitological diagnosis will be performed by triple coproscopy using formalin - ethyl acetate concentration technique \[Truant AL, Elliott SH\] and iodine stained smears \[King M.\]. For preparations staining Lugol's solution will be used. The intensity of protozoa will be estimated by the number of protozoa in the field of view (ocular x10, objective x40) in iodine stained smears taken before application of formalin - ethyl acetate concentration technique, the number of protozoa will be calculated at least in 10 fields of view. 1-2, 3-4 and 5-6 microorganisms in a field of view were considered as infection of low, mean and high intensity respectively. For detection of C. parvum modified Ziehl - Neelsen method \[Henricksen SA, Pohlenz JF\] will be used for staining the preparations. The stained smears will be scanned with ×100 oil immersion lens for the presence of C. parvum.
Microbiological methods Microbiological methods wil be conducted for detection pathogenic bacteria, including Clostridium difficile, Salmonella spp, Shigella spp, Campylobacter spp, Yersinia spp, and Mycobacteria only from UC patients infected with B. hominis before therapy. If intestinal pathogenic bacteria are detected participants will be excluded from further investigation.
Collection of stool samples. Fecal samples will be collected from UC patients infected with B. hominis before therapy in sterile, wide-mouth, screw capped containers and immediately transferred to the laboratory, preferably within 2 h. Specimens will be processed for microscopy, anaerobic and aerobic culture, and ELISA (only for Clostridium difficile).
Procedures Parasitological examination in UC patients and population will be provided. Additional UC patients infected with B. hominis will be divided into 3 cohorts, in double-blinded fashion, to receive 1 of the following treatments: (1) patients with UC infected with B. hominis will be treated with nitazoxanide, 1.0 g/daily (two pills) twice over orally for 14 consecutive days; (2) UC patients infected with B. hominis will be treated with nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days; (3) patients with UC infected B. hominis will be treated with mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days. Except drugs patients of all three groups adhered to the diet. The purpose of follow-up was to monitor compliance with medications and to record response to therapy, adverse events, and recurrence of symptoms.
Other detected pathogenic protozoan and helminthes was treated by standard dosage of antiparasitic drugs.
Follow-up The study was conducted in two stages. At the first stage parasitological examination of patients with UC before treatment and population will be provided . At the second stage of the study in patients with UC infected with B. hominis drugs with anti Blastocystis activity will be applied as well as monitoring of therapy efficiency. Parasitological, microbiological, clinical and endoscopic examination will be conducted before therapy and at the 2nd, 6th and 12th weeks. At each visit, a Mayo Clinic score will be calculated and intensity/elimination of B. hominis will be determined.
Outcome measures The outcome measures of therapy are : eradication/ reduction of intensity of B. hominis infection and a clinical response of UC patients at the 2nd, 6th and 12th weeks will be defined as a reduction in the Mayo Clinic score.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with ulcerative colitis
Patients with ulcerative colitis in this group will take nitazoxanide per os
parasitological diagnostics (coproscopy)
Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
Nitazoxanide 500Mg Oral Tablet
Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
Participants (control group)
only parasitological diagnostics will be performed in this group to compare the prevalence of some representatives of the microbiota
No interventions assigned to this group
UC patients (cohort 1)
Patients with ulcerative colitis in this group will take standart therapy (mesalazin)
parasitological diagnostics (coproscopy)
Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
Mesalazine 250Mg
Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
UC patients (cohort 2)
Patients with ulcerative colitis in this group will take placebo tabletes
parasitological diagnostics (coproscopy)
Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
Placebo tabletes
Tab. Placebo (shugar pills) will be given to the participants
UC patients (cohort 3)
Patients with ulcerative colitis in this group will take combination standart therapy with nitazoxanide
parasitological diagnostics (coproscopy)
Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet
Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
parasitological diagnostics (coproscopy)
Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
Nitazoxanide 500Mg Oral Tablet
Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet
Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
Mesalazine 250Mg
Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
Placebo tabletes
Tab. Placebo (shugar pills) will be given to the participants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Residents of Tashkent region which does not have any complaints from the gastrointestinal tract (control group)
Exclusion Criteria
* Patients with a toxic megacolon,
* Patients with a abdominal abscess, -
* Patients with a symptomatic colonic stricture,
* Patients with a stoma,
* Patients with a a history of colectomy,
* An increased risk of infectious complications (e.g. as a result of recent pyogenic infection, enteric pathogens detected on stool analysis, active or latent tuberculosis, immunodeficiency, hepatitis B or C, or recent live vaccination),
* Clinically meaningful laboratory abnormalities,
* Pregnancy or lactation,
* An unstable or uncontrolled medical disorder,
* An anticipated requirement for major surgery,
* Colonic dysplasia or adenomas,
* Malignant neoplasms.
* Patients which operated,
* Ever used immunosuppressants or biological drugs
* In the presence of pathologic bacteria in gut microbiota, including Clostridium difficile, Salmonella spp, Shigella spp, Campylobacter spp, Yersinia spp, and Mycobacteria.
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Svetlana Osipova, MD, PhD, DS
MD, PhD, DS
References
Explore related publications, articles, or registry entries linked to this study.
Toychiev A, Navruzov B, Pazylova D, Davis N, Badalova N, Osipova S. Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease. Acta Trop. 2021 Jan;213:105755. doi: 10.1016/j.actatropica.2020.105755. Epub 2020 Nov 11.
Related Links
Access external resources that provide additional context or updates about the study.
Article in Pubmed
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#15.21.2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.